Evaluation of Ruxolitinib and Lenalidomide Combination as a Therapy for Patients With Myelofibrosis.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Lenalidomide (Primary) ; Ruxolitinib (Primary) ; Prednisone
- Indications Myelofibrosis
- Focus Therapeutic Use
- 28 Sep 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 03 Dec 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017 as per ClinicalTrials.gov record.
- 24 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov.